Pacira Pharma (PCRX): Exparel Sales Recovering, Reiterate Outperform - Wedbush
Tweet Send to a Friend
With the rescinded FDA warning letter not completely in Pacira Pharma's (NASDAQ: PCRX)
rear-view mirror and a new promotional strategy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
rear-view mirror and a new promotional strategy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE